There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Encompass Health (EHC – Research Report), Universal Health (UHS – Research Report) and Viking Therapeutics (VKTX – Research Report) with bullish sentiments.
Encompass Health (EHC)
In a report released today, David S Macdonald from Truist Financial maintained a Buy rating on Encompass Health. The company’s shares closed last Wednesday at $82.80, close to its 52-week high of $83.73.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Encompass Health with a $91.57 average price target, implying an 11.2% upside from current levels. In a report issued on April 15, Barclays also maintained a Buy rating on the stock with a $101.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Universal Health (UHS)
In a report released today, Kevin Fischbeck from Bank of America Securities reiterated a Buy rating on Universal Health, with a price target of $205.00. The company’s shares closed last Wednesday at $165.90.
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of
Universal Health has an analyst consensus of Moderate Buy, with a price target consensus of $187.64, representing a 14.3% upside. In a report issued on April 12, Deutsche Bank also maintained a Buy rating on the stock with a $203.00 price target.
Viking Therapeutics (VKTX)
Truist Financial analyst Joon Lee reiterated a Buy rating on Viking Therapeutics today. The company’s shares closed last Wednesday at $65.07.
According to TipRanks.com, Lee is a 5-star analyst with an average return of
Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $113.50, which is a 72.6% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EHC:
- Encompass Health Enhances Investor Insights with Adjusted Financials
- Encompass Health reports results for first quarter 2024
- Encompass Health (EHC) Q1 Earnings Cheat Sheet
- Encompass Health to build 50-bed rehabilitation hospital in San Antonio
- Encompass Health price target raised to $101 from $95 at Barclays
